Although there are situations in which treatment can be terminated earlier in transient CH, it is recommended that these patients be treated up to three years of age to protect the majority of neurodevelopment which occurs in this period and is thyroid-hormone dependent and then assessed subsequently [1,5,8,9]. The gene discussed is TG; the disease is cyclic hematopoiesis.